Objective  To analyze the epidemiological trends and disease burden of Hodgkin's lymphoma in China from 1990 to 2019.
Methods  Based on data from the Global Burden of Disease 2019 survey (GBD 2019), we used incidence, mortality, disability-adjusted life years (DALY), years of life lost (YLL) and years lived with disability (YLD) and their standardized rates to analyze the epidemic trends and disease burden of Hodgkin's lymphoma in China from 1990 to 2019.
Results  From 1990 to 2019, the number of new cases of Hodgkin's lymphoma in China increased from 6,600 to 9,500, an increase of 42.68%, and the overall standardized incidence rate decreased from 0.65/100,000 to 0.57/100,000, a decrease of 11.12%, but it has rebounded since 2006. The number of deaths and standardized mortality rate decreased by 45.30% and 72.00%, respectively. The standardized rate of YLD increased by 66.77%, while standard-ized rates of DALY and YLL showed a decreasing trend of 73.31% and 74.82%, respectively. The incidence, mortality and DALY rates of different genders in-creased with age, but the incidence, mortality and DALY rates of males were higher than those of females.
Conclusion  From 1990 to 2019, the incidence rate of Hodgkin's lymphoma in China first decreased and then increased, the mortality rate and DALY rate showed a decreasing trend. Men and the elderly remain at high risk of the current disease burden of Hodgkin's lymphoma.

1.Connors JM, Cozen W, Steidl C, et al. Hodgkin lymphoma[J]. Nat Rev Dis Primers, 2020, 6(1): 1-25. DOI: 10.1038/s41572-020-0189-6.

2.Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.

3.Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016[J]. J Hematol Oncol, 2019, 12(1): 1-9. DOI: 10.1186/s13045-019-0785-7.

4.王芳旭, 陶立波, 董咚, 等. 中国霍奇金淋巴瘤患者疾病负担调查——基于一项在线问卷调查的研究[J].中国医疗保险, 2020, (1): 60-64. DOI: 10.19546/j.issn. 1674-3830.2020.1.012. [Wang FX, Tao LB, Dong D, et al. A survey of disease burden of Hodgkin's lymphoma patients in China—based on an online questionnaire research[J]. China Health Insurance, 2020, (1): 60-64.]

5.Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study[J]. J Hematol Oncoly, 2019, 12(1): 1-10. DOI: 10.1186/s130 45-019-0706-9. 

6.Yang J, Li Y, Liu Q, et al. Brief introduction of medical database and data mining technology in big data era[J]. J Evid Based Med, 2020, 13(1): 57-69. DOI: 10.1111/jebm. 12373.

7.Wu WT, Li YJ, Feng AZ, et al. Data mining in clinical big data: the frequently used databases, steps, and methodological models[J]. Mil Med Res, 2021, 8(1): 1-12. DOI: 10.1186/s40779-021-00338-z.

8.Kyu HH, Abate D, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2018, 392(10159): 1859-1922. DOI: 10.1016/S0140-6736(18)32335-3.

9.Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. DOI: 10.1182/blood-2016-01-643569. 

10Chang ET, Canchola AJ, Cockburn M, et al. Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies in the California teachers study[J]. Blood, 2011, 118(6): 1591-1599. DOI: 10.1182/blood-2011-02-336065. 

11.Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas[J]. N Engl J Med, 2010, 363(19): 1812-1821. DOI: 10.1056/NEJMoa1002965.

12.于颖，邱录贵，易树华. 维布妥昔单抗在霍奇金淋巴瘤中的应用[J].白血病·淋巴瘤, 2020, 29(9): 519-524. DOI: 10.3760/cma.j.cn115356-20200417-00097.[Yu Y, Qiu LG, Yi SH. Application of brentuximab vedotin in Hodgkin lymphoma[J]. Journal of Leukemia and Lymphoma, 2020, 29(9): 519-524.]

13.Maggioncalda A, Malik N, Shenoy P, et al. Clinical, molecular, and environmental risk factors for Hodgkin lymphoma[J]. Adv Hematol, 2011: 736261. DOI: 10.1155/ 2011/736261.

14.中国抗癌协会淋巴瘤专业委员会,中国医师协会肿瘤医师分会,中国医疗保健国际交流促进会肿瘤内科分会.中国淋巴瘤治疗指南(2021年版)[J].中华肿瘤杂志, 2021, 43(7): 707-735. DOI: 10.3760/cma.j.cn112152-20210516-00382.[Chinese Anti-Cancer Association Lymphoma Committee, Chinese Association for Clinical Oncologists, Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare. Clinical practice guideline for lympoma in China[J]. Chinese Journal of Oncology, 2021, 43(7): 707-735.]

15.Islami F, Chen W, Yu X Q, et al. Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013[J]. Ann Oncol, 2017, 28(10): 2567-2574. DOI: 10.1093/annonc/mdx342. 

16.Xiong G, Zhang B, Huang M, et al. Epstein-Barr virus (EBV) infection in Chinese children: a retrospective study of age-specific prevalence[J]. PLoS One, 2014, 9(6): e99857. DOI: 10.1371/journal.pone.0099857.

17.Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27(47): 6550-6557. DOI: 10.1016/j.vaccine.2009.08.048.

18.Thyss A, Saada E, Gastaud L, et al. Hodgkin's lymphoma in older patients: an orphan disease?[J]. Mediterr J Hematol Infect Dis, 2014, 6(1): e2014050. DOI: 10.4084/MJHID.2014.050. 

19.Keegan TH, Glaser SL, Clarke CA, et al. Body size, physical activity, and risk of Hodgkin's lymphoma in women[J]. Cancer Epidemiol Biomarkers Prev, 2006, 15(6): 1095-1101. DOI: 10.1158/1055-9965.EPI-06-0020.

20.Hjalgrim H, Seow A, Rostgaard K, et al. Changing patterns of Hodgkin lymphoma incidence in Singapore[J]. Int J Cancer, 2008, 123(3): 716-719. DOI: 10.1002/ijc.23504.

21.张艳. 淋巴瘤化疗患者接受优质护理的临床效果[J].中国医药指南, 2021, 19(1): 141-142. DOI: 10.15912/j.cnki.gocm.2021.01.064.[Zhang Y. Clinical evaluation of patients with lymphoma chemotherapy receiving high-quality nursing[J]. Guide of China Medicine, 2021, 19(1): 141-142.]

22.Meng Q, Xu L, Zhang Y, et al. Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study[J]. Lancet, 2012, 379(9818): 805-814. DOI: 10.1016/S0140-6736(12) 60278-5. 

23.Meng Q, Fang H, Liu X, et al. Consolidating the social health insurance schemes in China: towards an equitable and efficient health system[J]. Lancet, 2015, 386(10002): 1484-1492. DOI: 10.1016/S0140-6736(15)00342-6.